ArticleFrontiers in medicine2026
Effectiveness of free vastus lateralis musculocutaneous flap transplantation plus ultrasound-mediated transdermal Qianjin Weijing decoction for chronic empyema: a prospective, preference-based observational study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effectiveness of free vastus lateralis musculocutaneous flap (VLMCF) transplantation combined with ultrasound-mediated delivery of Qianjin Weijing decoction for chronic empyema. Methods: In this single-center prospective observational study (July 2023-June 2025), 114 patients elected either VLMCF surgery alone (control, Results: At 2 weeks, the combined-therapy group showed a significantly greater reduction in cavity volume compared to the control (20.52 \ ± 4.45 vs. 24.40 \ ± 6.35 mL; adjusted mean difference: -3.72 mL; 95% CI: -5.85 to -1.59; Conclusion: Adding ultrasound-mediated Qianjin Weijing decoction to VLMCF transplantation may accelerate early cavity resolution and improve procalcitonin profiles in chronic empyema patients. While mid-term functional and nutritional outcomes were similar to surgery alone, the combined regimen is a safe potential adjunct. Randomized controlled trials are needed to confirm long-term benefits and causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.